View ValuationSofiva GenomicsLtd 将来の成長Future 基準チェック /06現在、 Sofiva GenomicsLtdの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare 収益成長17.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 15First quarter 2026 earnings released: EPS: NT$0.67 (vs NT$0.15 loss in 1Q 2025)First quarter 2026 results: EPS: NT$0.67 (up from NT$0.15 loss in 1Q 2025). Revenue: NT$93.0m (down 3.0% from 1Q 2025). Net income: NT$14.5m (up NT$17.7m from 1Q 2025). Profit margin: 16% (up from net loss in 1Q 2025). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 13Full year 2025 earnings released: NT$0.43 loss per share (vs NT$0.86 profit in FY 2024)Full year 2025 results: NT$0.43 loss per share (down from NT$0.86 profit in FY 2024). Revenue: NT$385.7m (down 15% from FY 2024). Net loss: NT$9.36m (down 151% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.お知らせ • Mar 12Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 03, 2026Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 03, 2026. Location: 3 floor no,195, hsing chung rd., neihu district, taipei city TaiwanBoard Change • Feb 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yi Shan Pan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 15Third quarter 2025 earnings released: NT$0.05 loss per share (vs NT$0.081 profit in 3Q 2024)Third quarter 2025 results: NT$0.05 loss per share (down from NT$0.081 profit in 3Q 2024). Revenue: NT$93.4m (down 12% from 3Q 2024). Net loss: NT$1.17m (down 167% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 15Second quarter 2025 earnings released: NT$0.02 loss per share (vs NT$0.45 profit in 2Q 2024)Second quarter 2025 results: NT$0.02 loss per share (down from NT$0.45 profit in 2Q 2024). Revenue: NT$100.7m (down 18% from 2Q 2024). Net loss: NT$410.0k (down 104% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.New Risk • Jul 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Profit margins are more than 30% lower than last year (0.6% net profit margin). Market cap is less than US$100m (NT$702.9m market cap, or US$23.8m).Buy Or Sell Opportunity • Jul 22Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to NT$30.00. The fair value is estimated to be NT$38.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.5% over the last 3 years. Earnings per share has declined by 50%.Upcoming Dividend • Jun 22Upcoming dividend of NT$0.30 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 21 July 2025. The company is paying out more than 100% of its profits and is paying out 81% of its cash flow. Trailing yield: 0.9%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (3.7%).Declared Dividend • Jun 07Dividend increased to NT$0.30Dividend of NT$0.30 is 51% higher than last year. Ex-date: 27th June 2025 Payment date: 21st July 2025 Dividend yield will be 0.9%, which is lower than the industry average of 3.1%. Payout Ratios Payout ratio: 240%. Cash payout ratio: 81%.New Risk • May 15New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.6% Last year net profit margin: 4.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.6% net profit margin). Market cap is less than US$100m (NT$729.9m market cap, or US$24.2m).お知らせ • May 07Sofiva Genomics Co.,Ltd. to Report Q1, 2025 Results on May 14, 2025Sofiva Genomics Co.,Ltd. announced that they will report Q1, 2025 results on May 14, 2025Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$32.65, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 17x in the Healthcare industry in Taiwan. Total loss to shareholders of 25% over the past three years.お知らせ • Mar 13Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 04, 2025Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 04, 2025. Location: 3 floor no,195, hsing chung rd., neihu district, taipei city TaiwanNew Risk • Nov 19New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.5% Last year net profit margin: 7.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (4.5% net profit margin). Market cap is less than US$100m (NT$868.1m market cap, or US$26.7m).お知らせ • Nov 06Sofiva Genomics Co.,Ltd. to Report Q3, 2024 Results on Nov 13, 2024Sofiva Genomics Co.,Ltd. announced that they will report Q3, 2024 results on Nov 13, 2024Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.45 (vs NT$0.20 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.45 (up from NT$0.20 in 2Q 2023). Revenue: NT$122.6m (up 2.9% from 2Q 2023). Net income: NT$9.55m (up 124% from 2Q 2023). Profit margin: 7.8% (up from 3.6% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.お知らせ • Aug 08Sofiva Genomics Co.,Ltd. to Report Q2, 2024 Results on Aug 14, 2024Sofiva Genomics Co.,Ltd. announced that they will report Q2, 2024 results on Aug 14, 2024Valuation Update With 7 Day Price Move • Jul 25Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to NT$65.20, the stock trades at a trailing P/E ratio of 70.3x. Average trailing P/E is 22x in the Healthcare industry in Taiwan. Total returns to shareholders of 45% over the past three years.Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$74.00, the stock trades at a trailing P/E ratio of 79.7x. Average trailing P/E is 25x in the Healthcare industry in Taiwan. Total returns to shareholders of 68% over the past three years.Upcoming Dividend • Jun 26Upcoming dividend of NT$0.20 per shareEligible shareholders must have bought the stock before 03 July 2024. Payment date: 26 July 2024. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of Taiwanese dividend payers (4.2%). Lower than average of industry peers (3.1%).Declared Dividend • Jun 06Dividend reduced to NT$0.20Dividend of NT$0.20 is 80% lower than last year. Ex-date: 3rd July 2024 Payment date: 26th July 2024 Dividend yield will be 0.3%, which is lower than the industry average of 3.1%.New Risk • Jun 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings have declined by 14% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (4.2% net profit margin). Market cap is less than US$100m (NT$1.20b market cap, or US$37.0m).Valuation Update With 7 Day Price Move • May 31Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$56.60, the stock trades at a trailing P/E ratio of 61x. Average trailing P/E is 23x in the Healthcare industry in Taiwan. Total returns to shareholders of 33% over the past three years.Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.58 (vs NT$0.20 in 1Q 2023)First quarter 2024 results: EPS: NT$0.58 (up from NT$0.20 in 1Q 2023). Revenue: NT$121.0m (up 7.1% from 1Q 2023). Net income: NT$12.5m (up 198% from 1Q 2023). Profit margin: 10% (up from 3.7% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.お知らせ • May 09Sofiva Genomics Co.,Ltd. to Report Q1, 2024 Results on May 15, 2024Sofiva Genomics Co.,Ltd. announced that they will report Q1, 2024 results on May 15, 2024New Risk • Apr 03New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.5% Last year net profit margin: 8.6% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.5% net profit margin). Market cap is less than US$100m (NT$880.1m market cap, or US$27.5m).お知らせ • Mar 16Sofiva Genomics Co.,Ltd., Annual General Meeting, May 29, 2024Sofiva Genomics Co.,Ltd., Annual General Meeting, May 29, 2024.Reported Earnings • Nov 14Third quarter 2023 earnings released: EPS: NT$0.27 (vs NT$0.12 in 3Q 2022)Third quarter 2023 results: EPS: NT$0.27 (up from NT$0.12 in 3Q 2022). Revenue: NT$119.9m (flat on 3Q 2022). Net income: NT$5.77m (up 127% from 3Q 2022). Profit margin: 4.8% (up from 2.1% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 09Sofiva Genomics Co.,Ltd. Announces Resignation of Su,Yining as CEOSofiva Genomics Co.,Ltd. announced resignation of SU,YINING as CEO. Effective date: November 7, 2023.Reported Earnings • Aug 13Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$0.28 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.20 (down from NT$0.28 in 2Q 2022). Revenue: NT$119.1m (down 8.2% from 2Q 2022). Net income: NT$4.27m (down 28% from 2Q 2022). Profit margin: 3.6% (down from 4.6% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$44.95, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 23x in the Healthcare industry in Taiwan. Total loss to shareholders of 17% over the past three years.Upcoming Dividend • Jun 30Upcoming dividend of NT$1.00 per share at 2.5% yieldEligible shareholders must have bought the stock before 07 July 2023. Payment date: 31 July 2023. Payout ratio is a comfortable 65% but the company is not cash flow positive. Trailing yield: 2.5%. Lower than top quartile of Taiwanese dividend payers (5.5%). In line with average of industry peers (2.5%).お知らせ • Jun 15Sofiva Genomics Co.,Ltd. Declares Cash Dividend, Payable on July 31, 2023The board of directors of Sofiva Genomics Co.,Ltd. declared cash dividend to shareholders of TWD 1 per share. Total amount of cash dividends to shareholders is TWD 21,362,400. Ex-rights (Ex-dividend) date is July 07, 2023; Ex-rights (Ex-dividend) record date is July 15, 2023 and Payment date of cash dividend distribution July 31, 2023.Valuation Update With 7 Day Price Move • May 09Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$46.90, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 22x in the Healthcare industry in Taiwan. Total loss to shareholders of 14% over the past three years.Reported Earnings • Apr 06Full year 2022 earnings released: EPS: NT$2.00 (vs NT$2.68 in FY 2021)Full year 2022 results: EPS: NT$2.00 (down from NT$2.68 in FY 2021). Revenue: NT$495.8m (down 2.5% from FY 2021). Net income: NT$42.8m (down 25% from FY 2021). Profit margin: 8.6% (down from 11% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Aug 05Second quarter 2022 earnings: EPS misses analyst expectationsSecond quarter 2022 results: EPS: NT$0.28 (down from NT$0.93 in 2Q 2021). Revenue: NT$129.6m (down 2.7% from 2Q 2021). Net income: NT$5.92m (down 70% from 2Q 2021). Profit margin: 4.6% (down from 15% in 2Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 61%. Over the next year, revenue is forecast to grow 5.1%, compared to a 14% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.Upcoming Dividend • Jun 29Upcoming dividend of NT$2.00 per shareEligible shareholders must have bought the stock before 06 July 2022. Payment date: 28 July 2022. Payout ratio is a comfortable 68% and this is well supported by cash flows. Trailing yield: 4.4%. Lower than top quartile of Taiwanese dividend payers (6.3%). Higher than average of industry peers (3.3%).お知らせ • Jun 17Sofiva Genomics Co.,Ltd. Announces Cash Dividend, Payable on July 28, 2022Sofiva Genomics Co.,Ltd. announced cash dividend of TWD 42,724,800 or TWD 2 per share. Payment date of cash dividend distribution is July 28, 2022. Ex-rights (Ex-dividend) record date is July 12, 2022. Ex-rights (Ex-dividend) date is July 6, 2022.Reported Earnings • May 09First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: EPS: NT$0.67 (up from NT$0.42 in 1Q 2021). Revenue: NT$125.7m (flat on 1Q 2021). Net income: NT$14.3m (up 61% from 1Q 2021). Profit margin: 11% (up from 7.1% in 1Q 2021). Revenue missed analyst estimates by 14%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS NT$0.68 (vs NT$0.28 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$125.3m (up 1.8% from 3Q 2020). Net income: NT$14.4m (up 146% from 3Q 2020). Profit margin: 12% (up from 4.8% in 3Q 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS NT$0.93 (vs NT$0.40 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$133.2m (up 8.2% from 2Q 2020). Net income: NT$19.7m (up 134% from 2Q 2020). Profit margin: 15% (up from 6.8% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.Upcoming Dividend • Jul 05Upcoming dividend of NT$1.40 per shareEligible shareholders must have bought the stock before 12 July 2021. Payment date: 06 August 2021. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). In line with average of industry peers (3.1%).Reported Earnings • Jun 12First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: NT$124.6m (up 4.6% from 1Q 2020). Net income: NT$8.91m (down 15% from 1Q 2020). Profit margin: 7.1% (down from 8.8% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 17First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: NT$124.6m (up 4.6% from 1Q 2020). Net income: NT$8.91m (down 15% from 1Q 2020). Profit margin: 7.1% (down from 8.8% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$58.00, the stock trades at a trailing P/E ratio of 35.6x. Average trailing P/E is 18x in the Healthcare industry in Taiwan. Total loss to shareholders of 45% over the past three years.分析記事 • Apr 14Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Reported Earnings • Mar 30Full year 2020 earnings released: EPS NT$1.63 (vs NT$2.96 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$488.9m (down 4.0% from FY 2019). Net income: NT$34.6m (down 45% from FY 2019). Profit margin: 7.1% (down from 12% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.分析記事 • Mar 18Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)In this article we are going to estimate the intrinsic value of Sofiva Genomics Co.,Ltd. ( GTSM:6615 ) by taking the...分析記事 • Feb 24Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its DividendDividend paying stocks like Sofiva Genomics Co.,Ltd. ( GTSM:6615 ) tend to be popular with investors, and for good...分析記事 • Jan 27Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?It is hard to get excited after looking at Sofiva GenomicsLtd's (GTSM:6615) recent performance, when its stock has...Is New 90 Day High Low • Jan 27New 90-day low: NT$50.60The company is down 11% from its price of NT$56.70 on 29 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 4.0% over the same period.分析記事 • Jan 07Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Is New 90 Day High Low • Dec 28New 90-day low: NT$51.60The company is down 11% from its price of NT$58.20 on 30 September 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 1.0% over the same period.分析記事 • Dec 15A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)Does the December share price for Sofiva Genomics Co.,Ltd. ( GTSM:6615 ) reflect what it's really worth? Today, we will...Is New 90 Day High Low • Dec 11New 90-day low: NT$54.00The company is down 7.0% from its price of NT$58.20 on 11 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 2.0% over the same period.分析記事 • Nov 24Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its DividendToday we'll take a closer look at Sofiva Genomics Co.,Ltd. (GTSM:6615) from a dividend investor's perspective. Owning...Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS NT$0.28The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$123.1m (down 5.6% from 3Q 2019). Net income: NT$5.85m (down 67% from 3Q 2019). Profit margin: 4.8% (down from 13% in 3Q 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Nov 02New 90-day low: NT$55.00The company is down 8.0% from its price of NT$60.00 on 04 August 2020. The Taiwanese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 6.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Sofiva GenomicsLtd は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:6615 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202638382328N/A12/31/2025386-9715N/A9/30/2025393-10411N/A6/30/2025406-71423N/A3/31/20254283835N/A12/31/2024453181135N/A9/30/202446521-124N/A6/30/202447825-233N/A3/31/202447520-186N/A12/31/202346712-124N/A9/30/202347234-719N/A6/30/202347331-3014N/A3/31/202348333-2412N/A12/31/202249643-1917N/A9/30/202250137742N/A6/30/2022506496079N/A3/31/2022510627186N/A12/31/2021508576780N/A9/30/2021507537488N/A6/30/2021505447785N/A3/31/2021494336472N/A12/31/2020489354561N/A9/30/2020489372950N/A6/30/2020497482850N/A3/31/2020506595177N/A12/31/201950963N/A101N/A9/30/201950461N/A97N/A6/30/201948651N/A98N/A3/31/201946949N/A73N/A12/31/201845947N/A54N/A9/30/201845146N/A58N/A6/30/201844648N/A49N/A3/31/201843845N/A50N/A12/31/201742445N/A66N/A9/30/201741048N/A75N/A6/30/201739849N/A102N/A3/31/201738845N/A87N/A12/31/201638443N/A66N/A6/30/201637333N/A14N/A3/31/201635625N/A12N/A12/31/201534416N/A13N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6615の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6615の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6615の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6615の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6615の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6615の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/13 15:22終値2026/07/13 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sofiva Genomics Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Yenya KuoCapital Securities CorporationXiaowei HuangMasterlink Securities Investment Advisory
Reported Earnings • May 15First quarter 2026 earnings released: EPS: NT$0.67 (vs NT$0.15 loss in 1Q 2025)First quarter 2026 results: EPS: NT$0.67 (up from NT$0.15 loss in 1Q 2025). Revenue: NT$93.0m (down 3.0% from 1Q 2025). Net income: NT$14.5m (up NT$17.7m from 1Q 2025). Profit margin: 16% (up from net loss in 1Q 2025). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 13Full year 2025 earnings released: NT$0.43 loss per share (vs NT$0.86 profit in FY 2024)Full year 2025 results: NT$0.43 loss per share (down from NT$0.86 profit in FY 2024). Revenue: NT$385.7m (down 15% from FY 2024). Net loss: NT$9.36m (down 151% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 12Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 03, 2026Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 03, 2026. Location: 3 floor no,195, hsing chung rd., neihu district, taipei city Taiwan
Board Change • Feb 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yi Shan Pan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 15Third quarter 2025 earnings released: NT$0.05 loss per share (vs NT$0.081 profit in 3Q 2024)Third quarter 2025 results: NT$0.05 loss per share (down from NT$0.081 profit in 3Q 2024). Revenue: NT$93.4m (down 12% from 3Q 2024). Net loss: NT$1.17m (down 167% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 15Second quarter 2025 earnings released: NT$0.02 loss per share (vs NT$0.45 profit in 2Q 2024)Second quarter 2025 results: NT$0.02 loss per share (down from NT$0.45 profit in 2Q 2024). Revenue: NT$100.7m (down 18% from 2Q 2024). Net loss: NT$410.0k (down 104% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
New Risk • Jul 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Profit margins are more than 30% lower than last year (0.6% net profit margin). Market cap is less than US$100m (NT$702.9m market cap, or US$23.8m).
Buy Or Sell Opportunity • Jul 22Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to NT$30.00. The fair value is estimated to be NT$38.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.5% over the last 3 years. Earnings per share has declined by 50%.
Upcoming Dividend • Jun 22Upcoming dividend of NT$0.30 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 21 July 2025. The company is paying out more than 100% of its profits and is paying out 81% of its cash flow. Trailing yield: 0.9%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (3.7%).
Declared Dividend • Jun 07Dividend increased to NT$0.30Dividend of NT$0.30 is 51% higher than last year. Ex-date: 27th June 2025 Payment date: 21st July 2025 Dividend yield will be 0.9%, which is lower than the industry average of 3.1%. Payout Ratios Payout ratio: 240%. Cash payout ratio: 81%.
New Risk • May 15New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.6% Last year net profit margin: 4.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.6% net profit margin). Market cap is less than US$100m (NT$729.9m market cap, or US$24.2m).
お知らせ • May 07Sofiva Genomics Co.,Ltd. to Report Q1, 2025 Results on May 14, 2025Sofiva Genomics Co.,Ltd. announced that they will report Q1, 2025 results on May 14, 2025
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$32.65, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 17x in the Healthcare industry in Taiwan. Total loss to shareholders of 25% over the past three years.
お知らせ • Mar 13Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 04, 2025Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 04, 2025. Location: 3 floor no,195, hsing chung rd., neihu district, taipei city Taiwan
New Risk • Nov 19New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.5% Last year net profit margin: 7.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (4.5% net profit margin). Market cap is less than US$100m (NT$868.1m market cap, or US$26.7m).
お知らせ • Nov 06Sofiva Genomics Co.,Ltd. to Report Q3, 2024 Results on Nov 13, 2024Sofiva Genomics Co.,Ltd. announced that they will report Q3, 2024 results on Nov 13, 2024
Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.45 (vs NT$0.20 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.45 (up from NT$0.20 in 2Q 2023). Revenue: NT$122.6m (up 2.9% from 2Q 2023). Net income: NT$9.55m (up 124% from 2Q 2023). Profit margin: 7.8% (up from 3.6% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
お知らせ • Aug 08Sofiva Genomics Co.,Ltd. to Report Q2, 2024 Results on Aug 14, 2024Sofiva Genomics Co.,Ltd. announced that they will report Q2, 2024 results on Aug 14, 2024
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to NT$65.20, the stock trades at a trailing P/E ratio of 70.3x. Average trailing P/E is 22x in the Healthcare industry in Taiwan. Total returns to shareholders of 45% over the past three years.
Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$74.00, the stock trades at a trailing P/E ratio of 79.7x. Average trailing P/E is 25x in the Healthcare industry in Taiwan. Total returns to shareholders of 68% over the past three years.
Upcoming Dividend • Jun 26Upcoming dividend of NT$0.20 per shareEligible shareholders must have bought the stock before 03 July 2024. Payment date: 26 July 2024. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of Taiwanese dividend payers (4.2%). Lower than average of industry peers (3.1%).
Declared Dividend • Jun 06Dividend reduced to NT$0.20Dividend of NT$0.20 is 80% lower than last year. Ex-date: 3rd July 2024 Payment date: 26th July 2024 Dividend yield will be 0.3%, which is lower than the industry average of 3.1%.
New Risk • Jun 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings have declined by 14% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (4.2% net profit margin). Market cap is less than US$100m (NT$1.20b market cap, or US$37.0m).
Valuation Update With 7 Day Price Move • May 31Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$56.60, the stock trades at a trailing P/E ratio of 61x. Average trailing P/E is 23x in the Healthcare industry in Taiwan. Total returns to shareholders of 33% over the past three years.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.58 (vs NT$0.20 in 1Q 2023)First quarter 2024 results: EPS: NT$0.58 (up from NT$0.20 in 1Q 2023). Revenue: NT$121.0m (up 7.1% from 1Q 2023). Net income: NT$12.5m (up 198% from 1Q 2023). Profit margin: 10% (up from 3.7% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
お知らせ • May 09Sofiva Genomics Co.,Ltd. to Report Q1, 2024 Results on May 15, 2024Sofiva Genomics Co.,Ltd. announced that they will report Q1, 2024 results on May 15, 2024
New Risk • Apr 03New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.5% Last year net profit margin: 8.6% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.5% net profit margin). Market cap is less than US$100m (NT$880.1m market cap, or US$27.5m).
お知らせ • Mar 16Sofiva Genomics Co.,Ltd., Annual General Meeting, May 29, 2024Sofiva Genomics Co.,Ltd., Annual General Meeting, May 29, 2024.
Reported Earnings • Nov 14Third quarter 2023 earnings released: EPS: NT$0.27 (vs NT$0.12 in 3Q 2022)Third quarter 2023 results: EPS: NT$0.27 (up from NT$0.12 in 3Q 2022). Revenue: NT$119.9m (flat on 3Q 2022). Net income: NT$5.77m (up 127% from 3Q 2022). Profit margin: 4.8% (up from 2.1% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 09Sofiva Genomics Co.,Ltd. Announces Resignation of Su,Yining as CEOSofiva Genomics Co.,Ltd. announced resignation of SU,YINING as CEO. Effective date: November 7, 2023.
Reported Earnings • Aug 13Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$0.28 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.20 (down from NT$0.28 in 2Q 2022). Revenue: NT$119.1m (down 8.2% from 2Q 2022). Net income: NT$4.27m (down 28% from 2Q 2022). Profit margin: 3.6% (down from 4.6% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$44.95, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 23x in the Healthcare industry in Taiwan. Total loss to shareholders of 17% over the past three years.
Upcoming Dividend • Jun 30Upcoming dividend of NT$1.00 per share at 2.5% yieldEligible shareholders must have bought the stock before 07 July 2023. Payment date: 31 July 2023. Payout ratio is a comfortable 65% but the company is not cash flow positive. Trailing yield: 2.5%. Lower than top quartile of Taiwanese dividend payers (5.5%). In line with average of industry peers (2.5%).
お知らせ • Jun 15Sofiva Genomics Co.,Ltd. Declares Cash Dividend, Payable on July 31, 2023The board of directors of Sofiva Genomics Co.,Ltd. declared cash dividend to shareholders of TWD 1 per share. Total amount of cash dividends to shareholders is TWD 21,362,400. Ex-rights (Ex-dividend) date is July 07, 2023; Ex-rights (Ex-dividend) record date is July 15, 2023 and Payment date of cash dividend distribution July 31, 2023.
Valuation Update With 7 Day Price Move • May 09Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$46.90, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 22x in the Healthcare industry in Taiwan. Total loss to shareholders of 14% over the past three years.
Reported Earnings • Apr 06Full year 2022 earnings released: EPS: NT$2.00 (vs NT$2.68 in FY 2021)Full year 2022 results: EPS: NT$2.00 (down from NT$2.68 in FY 2021). Revenue: NT$495.8m (down 2.5% from FY 2021). Net income: NT$42.8m (down 25% from FY 2021). Profit margin: 8.6% (down from 11% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 05Second quarter 2022 earnings: EPS misses analyst expectationsSecond quarter 2022 results: EPS: NT$0.28 (down from NT$0.93 in 2Q 2021). Revenue: NT$129.6m (down 2.7% from 2Q 2021). Net income: NT$5.92m (down 70% from 2Q 2021). Profit margin: 4.6% (down from 15% in 2Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 61%. Over the next year, revenue is forecast to grow 5.1%, compared to a 14% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
Upcoming Dividend • Jun 29Upcoming dividend of NT$2.00 per shareEligible shareholders must have bought the stock before 06 July 2022. Payment date: 28 July 2022. Payout ratio is a comfortable 68% and this is well supported by cash flows. Trailing yield: 4.4%. Lower than top quartile of Taiwanese dividend payers (6.3%). Higher than average of industry peers (3.3%).
お知らせ • Jun 17Sofiva Genomics Co.,Ltd. Announces Cash Dividend, Payable on July 28, 2022Sofiva Genomics Co.,Ltd. announced cash dividend of TWD 42,724,800 or TWD 2 per share. Payment date of cash dividend distribution is July 28, 2022. Ex-rights (Ex-dividend) record date is July 12, 2022. Ex-rights (Ex-dividend) date is July 6, 2022.
Reported Earnings • May 09First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: EPS: NT$0.67 (up from NT$0.42 in 1Q 2021). Revenue: NT$125.7m (flat on 1Q 2021). Net income: NT$14.3m (up 61% from 1Q 2021). Profit margin: 11% (up from 7.1% in 1Q 2021). Revenue missed analyst estimates by 14%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS NT$0.68 (vs NT$0.28 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$125.3m (up 1.8% from 3Q 2020). Net income: NT$14.4m (up 146% from 3Q 2020). Profit margin: 12% (up from 4.8% in 3Q 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS NT$0.93 (vs NT$0.40 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$133.2m (up 8.2% from 2Q 2020). Net income: NT$19.7m (up 134% from 2Q 2020). Profit margin: 15% (up from 6.8% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
Upcoming Dividend • Jul 05Upcoming dividend of NT$1.40 per shareEligible shareholders must have bought the stock before 12 July 2021. Payment date: 06 August 2021. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). In line with average of industry peers (3.1%).
Reported Earnings • Jun 12First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: NT$124.6m (up 4.6% from 1Q 2020). Net income: NT$8.91m (down 15% from 1Q 2020). Profit margin: 7.1% (down from 8.8% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 17First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: NT$124.6m (up 4.6% from 1Q 2020). Net income: NT$8.91m (down 15% from 1Q 2020). Profit margin: 7.1% (down from 8.8% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$58.00, the stock trades at a trailing P/E ratio of 35.6x. Average trailing P/E is 18x in the Healthcare industry in Taiwan. Total loss to shareholders of 45% over the past three years.
分析記事 • Apr 14Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
Reported Earnings • Mar 30Full year 2020 earnings released: EPS NT$1.63 (vs NT$2.96 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$488.9m (down 4.0% from FY 2019). Net income: NT$34.6m (down 45% from FY 2019). Profit margin: 7.1% (down from 12% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
分析記事 • Mar 18Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)In this article we are going to estimate the intrinsic value of Sofiva Genomics Co.,Ltd. ( GTSM:6615 ) by taking the...
分析記事 • Feb 24Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its DividendDividend paying stocks like Sofiva Genomics Co.,Ltd. ( GTSM:6615 ) tend to be popular with investors, and for good...
分析記事 • Jan 27Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?It is hard to get excited after looking at Sofiva GenomicsLtd's (GTSM:6615) recent performance, when its stock has...
Is New 90 Day High Low • Jan 27New 90-day low: NT$50.60The company is down 11% from its price of NT$56.70 on 29 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 4.0% over the same period.
分析記事 • Jan 07Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Is New 90 Day High Low • Dec 28New 90-day low: NT$51.60The company is down 11% from its price of NT$58.20 on 30 September 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 1.0% over the same period.
分析記事 • Dec 15A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)Does the December share price for Sofiva Genomics Co.,Ltd. ( GTSM:6615 ) reflect what it's really worth? Today, we will...
Is New 90 Day High Low • Dec 11New 90-day low: NT$54.00The company is down 7.0% from its price of NT$58.20 on 11 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 2.0% over the same period.
分析記事 • Nov 24Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its DividendToday we'll take a closer look at Sofiva Genomics Co.,Ltd. (GTSM:6615) from a dividend investor's perspective. Owning...
Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS NT$0.28The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$123.1m (down 5.6% from 3Q 2019). Net income: NT$5.85m (down 67% from 3Q 2019). Profit margin: 4.8% (down from 13% in 3Q 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Nov 02New 90-day low: NT$55.00The company is down 8.0% from its price of NT$60.00 on 04 August 2020. The Taiwanese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 6.0% over the same period.